Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.CBIO · Entity 5255 | Director | June 02, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date June 02, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.01 · Expires 2036-06-02 | Direct | 11,050 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 11,050 · Balance 11,050 F1: This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Nuvalent, Inc.
Report date July 15, 2026 · Filed July 15, 2026
Section 16 reporting ended · disclosed 2026-07-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Other · Disposed 44,433 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax. F2: (Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. |
| Class A Common Stock - Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 2
1 source rowRow 2 · 2026-07-15 · Disposition to issuer · Disposed 41,100 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company. F4: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price. |
| Class A Common Stock - Performance Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-07-15 transaction · row 4
2 source rows · reconciled sequenceRow 3 · 2026-07-15 · Grant · Acquired 14,350 · Balance 14,350 F5: Represents vesting of 5,600 Company PSUs (as defined below) that were granted to the Reporting Person on January 6, 2025, and 8,750 Company PSUs that were granted to the Reporting Person on January 7, 2026, and vested pursuant to the Merger Agreement. Row 4 · 2026-07-15 · Disposition to issuer · Disposed 14,350 · Balance 0 F6: Pursuant to the Merger Agreement, each restricted stock unit that was subject to time- and performance-based vesting (a "Company PSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company PSU immediately prior to the effective time of the Merger, assuming applicable performance goals were achieved in full, and (y) the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2031-02-16 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-15 · Disposition to issuer · Disposed 131,637 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.89 · Expires 2031-04-29 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Disposition to issuer · Disposed 8,016 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.93 · Expires 2032-01-04 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-15 · Disposition to issuer · Disposed 22,933 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.85 · Expires 2033-01-06 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-15 · Disposition to issuer · Disposed 84,200 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.35 · Expires 2034-01-05 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-07-15 · Disposition to issuer · Disposed 33,646 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.09 · Expires 2035-01-06 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-07-15 · Disposition to issuer · Disposed 37,500 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.82 · Expires 2036-01-07 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-07-15 · Disposition to issuer · Disposed 17,500 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax.
F2: (Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
F3: Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company.
F4: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.
F5: Represents vesting of 5,600 Company PSUs (as defined below) that were granted to the Reporting Person on January 6, 2025, and 8,750 Company PSUs that were granted to the Reporting Person on January 7, 2026, and vested pursuant to the Merger Agreement.
F6: Pursuant to the Merger Agreement, each restricted stock unit that was subject to time- and performance-based vesting (a "Company PSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company PSU immediately prior to the effective time of the Merger, assuming applicable performance goals were achieved in full, and (y) the Offer Price.
F7: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2024 Filed Jul 2, 2024 20:44 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $27.85 | $0.00 |
DisclosureSEC source: 0000950170-24-080600 · ownership.xml · derivative · entry 5 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,200 Underlying: Class A Common Stock · 10,000 shares Expires 2033-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2023. F5 · derivative.exercise_date: The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:44 UTC | Nuvalent, Inc. NUVL · Entity 29892 | SaleClass A Common Stock | 572 | $76.73 | $43,889.56 |
DisclosureSEC source: 0000950170-24-080600 · ownership.xml · nonDerivative · entry 4 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,300 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.56 to $77.18, inclusive. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:44 UTC | Nuvalent, Inc. NUVL · Entity 29892 | SaleClass A Common Stock | 1,863 | $76.19 | $141,941.97 |
DisclosureSEC source: 0000950170-24-080600 · ownership.xml · nonDerivative · entry 3 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,872 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.56 to $76.55, inclusive. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:44 UTC | Nuvalent, Inc. NUVL · Entity 29892 | SaleClass A Common Stock | 7,565 | $75.15 | $568,509.75 |
DisclosureSEC source: 0000950170-24-080600 · ownership.xml · nonDerivative · entry 2 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,735 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.56 to $75.54, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:44 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Exercise / conversionClass A Common Stock | 10,000 | $27.85 | $278,500.00 |
DisclosureSEC source: 0000950170-24-080600 · ownership.xml · nonDerivative · entry 1 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2023. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:49 UTC | Nuvalent, Inc. NUVL · Entity 29892 | GrantStock Option (Right to Buy) · Derivative | 47,500 | $0.00 Strike: $72.35 | $0.00 |
DisclosureSEC source: 0000950170-24-003386 · ownership.xml · derivative · entry 2 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Class A Common Stock · 47,500 shares Expires 2034-01-05 F2 · derivative.exercise_date: The shares underlying this option vest over the next four years in equal monthly installments following January 5, 2024, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:49 UTC | Nuvalent, Inc. NUVL · Entity 29892 | GrantClass A Common Stock | 33,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-003386 · ownership.xml · nonDerivative · entry 1 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,300 F1 · shares: Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in three equal annual installments following January 5, 2024, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:51 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-23-059361 · doc4.xml · derivative · entry 3 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,884 Underlying: Class A Common Stock · 30,000 shares Expires 2031-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vested on January 25, 2022, and the remainder have vested or shall vest over the next three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:51 UTC | Nuvalent, Inc. NUVL · Entity 29892 | SaleClass A Common Stock | 30,000 | $75.82 | $2,274,600.00 |
DisclosureSEC source: 0001209191-23-059361 · doc4.xml · nonDerivative · entry 2 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.40 to $76.36, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:51 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Exercise / conversionClass A Common Stock | 30,000 | $1.08 | $32,400.00 |
DisclosureSEC source: 0001209191-23-059361 · doc4.xml · nonDerivative · entry 1 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 20:16 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-23-043954 · doc4.xml · derivative · entry 4 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,884 Underlying: Class A Common Stock · 25,000 shares Expires 2031-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 22, 2021. F4 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vested on January 25, 2022, and the remainder have vested or shall vest over the next three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 20:16 UTC | Nuvalent, Inc. NUVL · Entity 29892 | SaleClass A Common Stock | 10,848 | $49.49 | $536,867.52 |
DisclosureSEC source: 0001209191-23-043954 · doc4.xml · nonDerivative · entry 3 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 22, 2021. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.15 to $49.88, inclusive. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 20:16 UTC | Nuvalent, Inc. NUVL · Entity 29892 | SaleClass A Common Stock | 14,152 | $48.61 | $687,928.72 |
DisclosureSEC source: 0001209191-23-043954 · doc4.xml · nonDerivative · entry 2 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,848 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 22, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.11 to $48.90, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 20:16 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Exercise / conversionClass A Common Stock | 25,000 | $1.08 | $27,000.00 |
DisclosureSEC source: 0001209191-23-043954 · doc4.xml · nonDerivative · entry 1 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 22, 2021. Read SEC document |
| January 06, 2023 Filed Jan 6, 2023 21:45 UTC | Nuvalent, Inc. NUVL · Entity 29892 | GrantStock Option (Right to Buy) · Derivative | 144,200 | $0.00 Strike: $27.85 | $0.00 |
DisclosureSEC source: 0001209191-23-002367 · doc4.xml · derivative · entry 1 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,200 Underlying: Class A Common Stock · 144,200 shares Expires 2033-01-06 F1 · derivative.exercise_date: The shares underlying this option vest over the next four years in equal monthly installments following January 6, 2023, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 22:07 UTC | Nuvalent, Inc. NUVL · Entity 29892 | GrantStock Option (Right to Buy) · Derivative | 107,000 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000899243-22-000926 · doc4.xml · derivative · entry 1 Balcom Alexandra · CIK 0001862147 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 Underlying: Common Stock · 107,000 shares Expires 2032-01-04 F1 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on January 4, 2023, and the remainder vest over the next three years in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.